Nucleic Acid-Based Approaches to Tackle KRAS Mutant Cancers

Area of Science:

• Oncology
• Molecular Biology
• Drug Development

Background:

• Activating KRAS mutations are key drivers in numerous cancers.
• KRAS was historically considered undruggable, limiting therapeutic options.
• Advances in nucleic acid chemistry and delivery have enabled new therapeutic strategies.

Purpose of the Study:

• To review progress in targeting KRAS mutant cancers.
• To outline developments in nucleic acid-based therapeutic strategies.
• To provide insights into mechanisms, challenges, and clinical trials of these novel therapies.

Main Methods:

• Literature review of current research and clinical trials.
• Analysis of nucleic acid-based therapeutic strategies.
• Discussion of mechanisms of action and challenges.

Main Results:

• Nucleic acid-based therapeutics represent a paradigm shift in KRAS inhibition.
• Significant progress has been made in developing these next-generation drugs.
• Various strategies are under investigation, with ongoing clinical trials.

Conclusions:

• Nucleic acid-based strategies hold significant potential for treating KRAS mutant cancers.
• Overcoming existing challenges is crucial for clinical success.
• This approach offers a promising future for targeted cancer therapy.